Mercer Global Advisors’s Atea Pharmaceuticals AVIR Stock Holding History

Mercer Global Advisors’s Portfolio AVIR Stock Details AVIR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$130K	Buy	+27,860	New	+$139K	﹤0.01%	3636

Other funds holding AVIR

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

BCM

BML Capital Management Zionsville, Indiana $176M AUM 123.21% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

BCLSI

Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Mercer Global Advisors's AVIR Position: Q2 2026 in Review

Mercer Global Advisors opened a new position in Atea Pharmaceuticals (AVIR) in Q2 2026: 27,860 shares worth $130K. The stake represents ﹤0.01% of the portfolio and ranks #3636 among its holdings.

116 funds tracked by Wall St. Rank hold AVIR as of Q2 2026.

Mercer Global Advisors held 27,860 shares of Atea Pharmaceuticals worth $130K as of Q2 2026.
Atea Pharmaceuticals was a new Mercer Global Advisors position in Q2 2026.
Atea Pharmaceuticals made up ﹤0.01% of Mercer Global Advisors's portfolio in Q2 2026, its #3636 holding.
116 funds tracked by Wall St. Rank held Atea Pharmaceuticals as of Q2 2026.

Based on Mercer Global Advisors's 13F filing for Q2 2026, filed 11 Aug 2026.